CONCLUSION
Graft oozing is a worrying complication seemingly unique to the E-Vita Open NEO hybrid prosthesis, possibly resulting from its particularly porous graft material. Our experimental data have emphasised the significance of graft oozing in this device and made clear the need for this limitation to be addressed. The recommendation to use BioGlue as a priming agent to prevent oozing is controversial, as BioGlue, though safe and useful in certain surgical applications, is also associated with several major complications.5 These risks are further amplified considering the amount of BioGlue that would be needed to successfully prime the arch prosthesis, demonstrated by our data as well as by reports published in literature. Bearing the design limitations of E-Vita Open NEO and the added risk of graft oozing in mind, as well as the supplemental risks associated with BioGlue use, it is reasonable to suggest that the device falls short of the providing gold-standard results, especially in comparison to alternative commercially available devices, such as Thoraflex® HP.